The Agenus team is in Munich for ESMO - European Society for Medical Oncology's #ESMOGI24 annual meeting. Stay tuned tomorrow for new data from the NEST clinical trial on our botensilimab/balstilimab #immunotherapy combination in #neoadjuvant colon cancer. See the schedule: https://lnkd.in/ebR3idFf
Agenus’ Post
More Relevant Posts
-
Discussion on management of early-stage disease - International Association for the Study of Lung Cancer Narjust Florez M.D. Dana-Farber Cancer Institute Harvard Medical School ESMO - European Society for Medical Oncology #ChemoImmunotherapy #ESMO #Cancer #OncoDaily #Oncology #CancerPrevention
-
❇️ NEOPRISM-CRC is the first multicenter, phase 2 trial to determine the safety and efficacy of neoadjuvant #pembrolizumab when stratified by TMB for high-risk stage II-III #colorectal cancer. ❇️ Learn about the new study data presented at #ASCO24 by Dr. Kai-Keen Shiu of UCL Cancer Institute:
Neoadjuvant Pembrolizumab for Early-Stage dMMR/MSI-High CRC | Docwire News
docwirenews.com
-
Our commentary on the state of play of radiomics in Precision Oncology - Melvin L.K. Chua #Cancer #OncoDaily #Oncology #PrecisionMedicine #CancerCare
Melvin LK Chua: Our commentary on the state of play of radiomics in Precision Oncology - Oncodaily | Oncology News, Insights, Stories
oncodaily.com
-
Yardena Samuels discusses how ongoing research is revisiting the classic neoantigen approach - ESMO - European Society for Medical Oncology https://lnkd.in/g8YDjY8Q #oncodaily #oncology #cancer #research #neoantigens #cancerimmunotherapy #immunotherapy
Yardena Samuels discusses how ongoing research is revisiting the classic neoantigen approach - The European Society for Medical Oncology (ESMO) - OncoDaily
oncodaily.com
-
Check out the latest Oncology Insights article from Simone Ndujiuba, PharmD, BCOP discussing a new treatment for small cell lung cancer: https://bit.ly/3Vz97JE
-
Our phase 2 trial of SG+Pembro in platinum-resistant IO-naive 2L setting - Petros Grivas ECOG-ACRIN Cancer Research Group #Cancer #CancerResearch #JournalOfClinicalOncology #OncoDaily #Oncology
Petros Grivas: Our phase 2 trial of SG+Pembro in platinum-resistant IO-naive 2L setting - OncoDaily
oncodaily.com
-
See the discussion on our NEST-1trial by Rachna Shroff and Shaalan Beg - Pashtoon Kasi American Society of Clinical Oncology (ASCO) Rachna Shroff, MD, FASCO Shaalan Beg MD MBA FASCO #ASCO #Balstilimab #Cancer #CRCSM #GI24 #OncoDaily #Oncology #CancerCare
Pashtoon Kasi: See the discussion on our NEST-1trial by Rachna Shroff and Shaalan Beg - OncoDaily
oncodaily.com
-
Experts discuss the rapidly evolving treatment landscape for EGFR exon 20 insertion lung cancer, highlighting recent advancements in therapies. https://lnkd.in/eYFs8aPH #lcsm #cancer #oncology
EGFR Exon 20 Insertion NSCLC: A Comprehensive Overview
cancernetwork.com
-
We review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer - Paolo Tarantino AstraZeneca ESMO - European Society for Medical Oncology https://lnkd.in/gSY4s4Ej #ESMOOpen #BreastCancer #HER2low #bestpractices #futureperspectives #patientidentification #AstraZeneca #TDXd #cancertreatment #personalstory
Paolo Tarantino: We review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer - OncoDaily
oncodaily.com
Director of Business Development @ NJ Bio, Inc.
2moIf the data is real and pure, that bot/bal combo is beyond impressive. Wishing yall the best for AA, patients could really use it.